Infusion-related risks associated with chemotherapy

摘要

This article provides a comprehensive overview of the risks associated with the administration of chemotherapy, monoclonal antibodies and targeted or biological therapies in the management of solid tumours. The main physiological actions of these agents are discussed, with reference to the immediate infusion-related side effects and complications that may arise from an extravasation injury. The article focuses on the identification and early recognition of these risk factors to implement preventive measures and appropriate management strategies. Kang and Saif (2007) stated that 'infusion related reactions may be denned as any signs or symptoms experienced by a patient during the infusion of pharmacologic or biologic agents or any event occurring on the first day of drug administration.' Zetka (2012) suggested that all systemic anticancer therapies, whether chemotherapy, monoclonal antibodies or novel agents, have the potential to cause an infusion-related reaction. It is essential to develop an understanding of the presenting symptoms and management strategies to promote early recognition and prompt medical intervention to minimise complications. Certain classes of chemotherapy have a greater potential to cause an infusion-related reaction; these, in addition to the associated risks with monoclonal antibodies, are discussed in more detail.